Programme Overview

The Norfolk LHRH Medicines Optimisation Programme is an NHS-supported initiative designed to support the safe and clinically appropriate optimisation of three-monthly androgen deprivation therapy (ADT) for patients with prostate cancer. The programme combines structured patient engagement with clinical pathway support to help practices manage eligible cohorts while improving oversight of injection timing and PSA monitoring.

The initiative focuses on patients receiving long-acting LHRH analogue therapies in primary care. Eclipse searches, drawing on data from your core clinical system (such as EMIS or TPP), and digital questionnaires to stratify patients and identify those who may benefit from optimisation or additional monitoring support.

The programme will be delivered in two phases:

• Phase 1 – Zoladex LA 10.8 mg implant: a centrally coordinated opt-out engagement approach where clinically appropriate patients are informed of a planned switch to Staladex 11.25 mg implant at their next administration appointment.

• Phase 2 – Prostap 3 DCS 11.25 mg depot injection: an opt-in engagement approach inviting patients to consider optimisation.

Alongside medication optimisation, the programme provides a clinical wraparound layer highlighting patients who are overdue or approaching their next injection and flagging PSA monitoring status where available.

Patients will receive structured outreach via SMS or telephone and will be directed to a secure patient portal to review information and complete a questionnaire indicating their preference or requesting further discussion. A central Medicines Optimisation support line will be available for patient queries.

Your practice will be notified before any patient communication begins. Practices remain clinically responsible for reviewing patients, issuing prescriptions, and administering treatment.

What This Means for Your Practice

Once your practice activates the programme:

• Eligible patients will be identified through Eclipse searches, drawing on data from your core clinical system (such as EMIS or TPP), and digital questionnaires to stratify patients.

• Central communications will provide patients with information about the programme and capture preferences through a questionnaire.

• Patient outcomes will feed into the clinical pathway, allowing practices to view prioritised cohorts and manage prescribing decisions.

• The pathway will provide visibility of patients who are due or overdue their injection, alongside PSA monitoring prompts where applicable.

Practices retain full clinical responsibility for confirming suitability, prescribing medication, and administering injections.

Practice Participation Details

Please complete the details below to confirm participation and activate the programme for your practice.